首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7
【2h】

Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7

机译:识别人趋化因子受体CCR7的纳米抗体的工程。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The chemokine receptor CCR7 plays a pivotal role in health and disease. In particular, CCR7 controls homing of antigen-bearing dendritic cells and T cells to lymph nodes, where adaptive immune responses are initiated. However, CCR7 also guides T cells to inflamed synovium and thereby contributes to rheumatoid arthritis and promotes cancer cell migration and metastasis formation. Nanobodies have recently emerged as versatile tools to study G-protein-coupled receptor functions and are being tested in diagnostics and therapeutics. In this study, we designed a strategy to engineer novel nanobodies recognizing human CCR7. We generated a nanobody library based on a solved crystal structure of the nanobody Nb80 recognizing the β2-adrenergic receptor (β2AR) and by specifically randomizing two segments within complementarity determining region 1 (CDR1) and CDR3 of Nb80 known to interact with β2AR. We fused the nanobody library to one half of split-YFP in order to identify individual nanobody clones interacting with CCR7 fused to the other half of split-YFP using bimolecular fluorescence complementation. We present three novel nanobodies, termed Nb1, Nb5, and Nb38, that recognize human CCR7 without interfering with G-protein-coupling and downstream signaling. Moreover, we were able to follow CCR7 trafficking upon CCL19 triggering using Nb1, Nb5, and Nb38.
机译:趋化因子受体CCR7在健康和疾病中起关键作用。特别地,CCR7控制携带抗原的树突状细胞和T细胞归巢至淋巴结,在此开始适应性免疫反应。但是,CCR7还可引导T细胞滑膜发炎,从而促进类风湿关节炎并促进癌细胞迁移和转移形成。纳米抗体近来已成为研究G蛋白偶联受体功能的通用工具,并正在诊断和治疗中进行测试。在这项研究中,我们设计了一种策略来工程化识别人类CCR7的新型纳米抗体。我们基于识别出β2-肾上腺素能受体(β2AR)的纳米抗体Nb80的已解决晶体结构,并通过将已知与β2AR相互作用的Nb80的互补决定区1(CDR1)和CDR3内的两个片段特异性随机化,来生成纳米抗体文库。我们将纳米抗体文库融合到split-YFP的一半,以便使用双分子荧光互补识别与融合到split-YFP另一半的CCR7相互作用的单个纳米抗体克隆。我们介绍了三个新的纳米抗体,称为Nb1,Nb5和Nb38,可识别人CCR7而不会干扰G蛋白偶联和下游信号传导。此外,在使用Nb1,Nb5和Nb38触发CCL19时,我们能够跟踪CCR7交易。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号